Ganciclovir
Generic: GANCICLOVIR SODIUM
Basic Information
Manufacturer
Pharmascience Inc.
Product Type
HUMAN PRESCRIPTION DRUG
Route of Administration
INTRAVENOUS
FDA Set ID
3059c2da-d4a7-4aea-828c-20e671cb875c
Indications & Usage
1 INDICATIONS AND USAGE Ganciclovir Injection Ganciclovir Injection is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for the: treatment of CMV retinitis in immunocompromised adult patients, including patients with acquired immunodeficiency syndrome (AIDS).
( 1.1 ) prevention of CMV disease in adult transplant recipients at risk for CMV disease.
( 1.2 ) 1.1 Treatment of CMV Retinitis Ganciclovir Injection is indicated for the treatment of cytomegalovirus (CMV) retinitis in immunocompromised adult patients, including patients with acquired immunodeficiency syndrome (AIDS) [see Clinical Studies (14.1 )].
1.2 Prevention of CMV Disease in Transplant Recipients Ganciclovir Injection is indicated for the prevention of CMV disease in adult transplant recipients at risk for CMV disease [see Clinical Studies (14.2) ].
( 1.1 ) prevention of CMV disease in adult transplant recipients at risk for CMV disease.
( 1.2 ) 1.1 Treatment of CMV Retinitis Ganciclovir Injection is indicated for the treatment of cytomegalovirus (CMV) retinitis in immunocompromised adult patients, including patients with acquired immunodeficiency syndrome (AIDS) [see Clinical Studies (14.1 )].
1.2 Prevention of CMV Disease in Transplant Recipients Ganciclovir Injection is indicated for the prevention of CMV disease in adult transplant recipients at risk for CMV disease [see Clinical Studies (14.2) ].
Adverse Reactions
6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections of the labeling: Hematologic Toxicity [see Warnings and Precautions (5.1) ] Renal Impairment [see Warnings and Precautions (5.2) ] Impairment of Fertility [see Warnings and Precautions (5.3) ] Fetal Toxicity [see Warnings and Precautions (5.4) ] Mutagenesis and Carcinogenesis [see Warnings and Precautions (5.5) ] Most common adverse reactions and laboratory abnormalities reported in at least 20% of patients were: pyrexia, diarrhea, leukopenia, nausea, anemia, asthenia, headache, cough, decreased appetite, dyspnea, abdominal pain, sepsis, hyperhidrosis, and blood creatinine increased.
( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Pharmascience Inc.
at 1-888-550-6060 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
6.1 Clinical Trial Experience in Adult Patients Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect rates observed in practice.
The most common adverse reactions and laboratory abnormalities reported in at least 20% of patients were pyrexia, diarrhea, leukopenia, nausea, anemia, asthenia, headache, cough, decreased appetite, dyspnea, abdominal pain, sepsis, hyperhidrosis, and blood creatinine increased.
Selected adverse reactions that occurred during clinical trials of Ganciclovir Injection are summarized below, according to the participating study patient population.
Three controlled, randomized, phase 3 trials comparing Ganciclovir Injection and ganciclovir capsules for maintenance treatment of CMV retinitis have been completed.
During these trials, Ganciclovir Injection or ganciclovir capsules were prematurely discontinued in 9% of subjects because of adverse reactions.
Selected adverse reactions and laboratory abnormalities reported during the conduct of these controlled trials are summarized in Table 2 and Table 3, respectively Adverse Reactions in Patients with CMV Retinitis: Three controlled, randomized, phase 3 trials comparing Ganciclovir Injection and ganciclovir capsules for maintenance treatment of CMV retinitis have been completed.
During these trials, Ganciclovir Injection or ganciclovir capsules were prematurely discontinued in 9% of subjects because of adverse reactions.
Selected adverse reactions and laboratory abnormalities reported during the conduct of these controlled trials are summarized in Table 2 and Table 3, respectively [see Clinical Studies (14.1) ] .
Table 2.
Pooled Selected Adverse Reactions Reported in ≥ 5% of Subjects Comparing Ganciclovir Injection to Ganciclovir Capsules for Maintenance Treatment of CMV Retinitis Maintenance Treatment Studies Adverse Reaction Ganciclovir Injection (n=179) Ganciclovir Capsules (n=326) Pyrexia 48% 38% Diarrhea 44% 41% Leukopenia 41% 29% Anemia 25% 19% Total catheter events 22% 6% Catheter infection 9% 4% Catheter sepsis 8% 1% Other catheter related events 5% 1% Sepsis 15% 4% Decreased appetite 14% 15% Vomiting 13% 13% Infection 13% 9% Hyperhidrosis 12% 11% Chills 10% 7% Neuropathy peripheral 9% 8% Thrombocytopenia 6% 6% Pruritus 5% 6% Retinal detachment has been observed in subjects with CMV retinitis both before and after initiation of therapy with ganciclovir.
Its relationship to therapy with ganciclovir is unknown.
Retinal detachment occurred in 11% of patients treated with Ganciclovir Injection Retinal Detachment: Retinal detachment has been observed in subjects with CMV retinitis both before and after initiation of therapy with ganciclovir.
Its relationship to therapy with ganciclovir is unknown.
Retinal detachment occurred in 11% of patients treated with Ganciclovir Injection and in 8% of patients treated with ganciclovir capsules.
Table 3.
Selected Laboratory Abnormalities in Trials for Treatment of CMV Retinitis CMV Retinitis Treatment Pooled data from Treatment Studies: ICM 1653, ICM 1774 and AVI 034 Laboratory Abnormalities Ganciclovir Injection Mean time on therapy = 103 days, including allowed re-induction treatment periods 5 mg/kg/day (N=175) % Ganciclovir Capsules Mean time on therapy = 91 days, including allowed re-induction treatment periods 3000 mg/day (N=320) % Neutropenia with Absolute Neutrophil Count (ANC) per mcL: < 500 25% 18% 500 < 749 14% 17% 750 < 1000 26% 19% Anemia with Hemoglobin (g/dL): < 6.5 g/dL 5% 2% 6.5 < 8.0 16% 10% 8.0 < 9.5 26% 25% Serum Creatinine (mg/dL): ≥ 2.5 2% 1% ≥ 1.5 – < 2.5 14% 12% There have been three controlled clinical trials of Ganciclovir Injection for the prevention of CMV disease in transplant recipients.
Selected laboratory abnormalities are summarized in Table 4 and Table 5 below.
Adverse Reactions in Transplant Recipients: There have been three controlled clinical trials of Ganciclovir Injection for the prevention of CMV disease in transplant recipients.
Selected laboratory abnormalities are summarized in Table 4 and Table 5 below.
Table 4 shows the frequency of neutropenia and thrombocytopenia and Table 5 shows the frequency of elevated serum creatinine values observed in these trials Table 4 shows the frequency of neutropenia and thrombocytopenia and Table 5 shows the frequency of elevated serum creatinine values observed in these trials [see Clinical Studies (14.2) ] .
Table 4.
Laboratory Abnormalities in Controlled Trials Transplant Recipients who Received Ganciclovir Injection, Placebo or Control Ganciclovir Injection Heart Allograft Study ICM 1496.
Mean duration of treatment = 28 days Bone Marrow Allograft Study ICM 1570 and ICM 1689.
Mean duration of treatment = 45 days Ganciclovir Injection (n=76) Placebo (n=73) Ganciclovir Injection (n=57) Control (n=55) Neutropenia Absolute Neutrophil Count (ANC) per mcL < 500 4% 3% 12% 6% 500-1000 3% 8% 29% 17% Total ANC ≤ 1000/mcL 7% 11% 41% 23% Thrombocytopenia Platelet count per mcL < 25,000 3% 1% 32% 28% 25,000-50,000 5% 3% 25% 37% Total Platelet Count ≤ 50,000/mcL 8% 4% 57% 65% Table 5.
Serum Creatinine Levels in Controlled Trials - Transplant Recipients who Received Ganciclovir Injection or Placebo Serum Creatinine Levels (mg/dL) Heart Allograft ICM 1496 Bone Marrow Allograft ICM 1570 Bone Marrow Allograft ICM 1689 Ganciclovir Injection (n=76) Placebo Ganciclovir Injection Control Ganciclovir Injection Placebo (n=73) (n=20) (n=20) (n=37) (n=35) ≥ 2.5 mg/dL 18% 4% 20% 0% 0% 0% ≥ 1.5 - < 2.5 58% 69% 50% 35% 43% 44% Other Adverse Reactions in Clinical Trials in Patients with CMV Retinitis and in Transplant Recipients Adverse drug reactions with Ganciclovir Injection or ganciclovir capsules in controlled clinical studies in either subjects with AIDS or transplant recipients are listed below Adverse drug reactions with Ganciclovir Injection or ganciclovir capsules in controlled clinical studies in either subjects with AIDS or transplant recipients are listed below [see Clinical Studies (14) ].
All these events occurred in at least 3 subjects.
pancytopenia, bone marrow failure Blood and lymphatic disorders: pancytopenia, bone marrow failure arrhythmia Cardiac disorders: arrhythmia : tinnitus, ear pain, deafness Ear and labyrinth disorders : tinnitus, ear pain, deafness : visual impairment, vitreous disorders, eye pain, conjunctivitis, macular edema Eye disorders : visual impairment, vitreous disorders, eye pain, conjunctivitis, macular edema : nausea, abdominal pain, dyspepsia, flatulence, constipation, mouth ulceration, dysphagia, abdominal distention, pancreatitis, gastrointestinal perforation, eructation, dry mouth Gastrointestinal disorders : nausea, abdominal pain, dyspepsia, flatulence, constipation, mouth ulceration, dysphagia, abdominal distention, pancreatitis, gastrointestinal perforation, eructation, dry mouth : fatigue, injection site inflammation, edema, pain, malaise, asthenia, chest pain, multiple organ failure General disorders and administration site conditions : fatigue, injection site inflammation, edema, pain, malaise, asthenia, chest pain, multiple organ failure : hypersensitivity Immune system disorders : hypersensitivity candida infections including oral candidiasis, upper respiratory infection, influenza, urinary tract infection, cellulitis Infections and infestations: candida infections including oral candidiasis, upper respiratory infection, influenza, urinary tract infection, cellulitis : blood alkaline phosphatase increased, hepatic function abnormal, aspartate aminotransferase increased, alanine aminotransferase increased, creatinine clearance decreased Investigations : blood alkaline phosphatase increased, hepatic function abnormal, aspartate aminotransferase increased, alanine aminotransferase increased, creatinine clearance decreased weight decreased Metabolism and nutrition disorders: weight decreased back pain, myalgia, arthralgia, muscle spasms, leg cramps, myasthenia Musculoskeletal and connective tissue disorders: back pain, myalgia, arthralgia, muscle spasms, leg cramps, myasthenia headache, insomnia, dizziness, paresthesia, hypoesthesia, seizure, somnolence, dysgeusia (taste disturbance), tremor Nervous system disorders: headache, insomnia, dizziness, paresthesia, hypoesthesia, seizure, somnolence, dysgeusia (taste disturbance), tremor depression, confusional state, anxiety, agitation, psychotic disorder, thinking abnormal, abnormal dreams Psychiatric disorders: depression, confusional state, anxiety, agitation, psychotic disorder, thinking abnormal, abnormal dreams kidney failure, renal function abnormal, urinary frequency, hematuria Renal and urinary disorders: kidney failure, renal function abnormal, urinary frequency, hematuria cough, dyspnea Respiratory, thoracic and mediastinal disorders: cough, dyspnea dermatitis, alopecia, dry skin, urticaria, rash Skin and subcutaneous tissues disorders: dermatitis, alopecia, dry skin, urticaria, rash : hypotension, hypertension, phlebitis, vasodilation Vascular disorders : hypotension, hypertension, phlebitis, vasodilation 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of Ganciclovir Injection The following adverse reactions have been identified during post-approval use of Ganciclovir Injection or ganciclovir capsules.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
: hemolytic anemia, agranulocytosis, granulocytopenia Blood and lymphatic disorders : hemolytic anemia, agranulocytosis, granulocytopenia cardiac arrest, conduction disorder, torsade de pointes, ventricular tachycardia Cardiac disorders: cardiac arrest, conduction disorder, torsade de pointes, ventricular tachycardia congenital anomaly Congenital, familial and genetic disorders: congenital anomaly inappropriate antidiuretic hormone secretion Endocrine disorders: inappropriate antidiuretic hormone secretion cataracts, dry eyes Eye disorders: cataracts, dry eyes intestinal ulcer Gastrointestinal disorders: intestinal ulcer cholelithiasis, cholestasis, hepatic failure, hepatitis Hepatobiliary disorders: cholelithiasis, cholestasis, hepatic failure, hepatitis anaphylactic reaction, allergic reaction, vasculitis Immune system disorders: anaphylactic reaction, allergic reaction, vasculitis blood triglycerides increased Investigations: blood triglycerides increased acidosis, hypercalcemia, hyponatremia Metabolism and nutrition disorders: acidosis, hypercalcemia, hyponatremia arthritis, rhabdomyolysis Musculoskeletal and connective tissue disorders: arthritis, rhabdomyolysis dysesthesia, dysphasia, extrapyramidal disorder, facial paralysis, amnesia, anosmia, myelopathy, cerebrovascular accident, third cranial nerve paralysis, aphasia, encephalopathy, intracranial hypertension Nervous system disorders: dysesthesia, dysphasia, extrapyramidal disorder, facial paralysis, amnesia, anosmia, myelopathy, cerebrovascular accident, third cranial nerve paralysis, aphasia, encephalopathy, intracranial hypertension irritability, hallucinations Psychiatric disorders: irritability, hallucinations renal tubular disorder, hemolytic uremic syndrome Renal and urinary disorders: renal tubular disorder, hemolytic uremic syndrome infertility, testicular hypotrophy Reproductive system and breast disorders: infertility, testicular hypotrophy bronchospasm, pulmonary fibrosis Respiratory, thoracic and mediastinal disorders: bronchospasm, pulmonary fibrosis : exfoliative dermatitis, Stevens-Johnson syndrome Skin and subcutaneous tissues disorders : exfoliative dermatitis, Stevens-Johnson syndrome peripheral ischemia Vascular disorders: peripheral ischemia
( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Pharmascience Inc.
at 1-888-550-6060 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
6.1 Clinical Trial Experience in Adult Patients Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect rates observed in practice.
The most common adverse reactions and laboratory abnormalities reported in at least 20% of patients were pyrexia, diarrhea, leukopenia, nausea, anemia, asthenia, headache, cough, decreased appetite, dyspnea, abdominal pain, sepsis, hyperhidrosis, and blood creatinine increased.
Selected adverse reactions that occurred during clinical trials of Ganciclovir Injection are summarized below, according to the participating study patient population.
Three controlled, randomized, phase 3 trials comparing Ganciclovir Injection and ganciclovir capsules for maintenance treatment of CMV retinitis have been completed.
During these trials, Ganciclovir Injection or ganciclovir capsules were prematurely discontinued in 9% of subjects because of adverse reactions.
Selected adverse reactions and laboratory abnormalities reported during the conduct of these controlled trials are summarized in Table 2 and Table 3, respectively Adverse Reactions in Patients with CMV Retinitis: Three controlled, randomized, phase 3 trials comparing Ganciclovir Injection and ganciclovir capsules for maintenance treatment of CMV retinitis have been completed.
During these trials, Ganciclovir Injection or ganciclovir capsules were prematurely discontinued in 9% of subjects because of adverse reactions.
Selected adverse reactions and laboratory abnormalities reported during the conduct of these controlled trials are summarized in Table 2 and Table 3, respectively [see Clinical Studies (14.1) ] .
Table 2.
Pooled Selected Adverse Reactions Reported in ≥ 5% of Subjects Comparing Ganciclovir Injection to Ganciclovir Capsules for Maintenance Treatment of CMV Retinitis Maintenance Treatment Studies Adverse Reaction Ganciclovir Injection (n=179) Ganciclovir Capsules (n=326) Pyrexia 48% 38% Diarrhea 44% 41% Leukopenia 41% 29% Anemia 25% 19% Total catheter events 22% 6% Catheter infection 9% 4% Catheter sepsis 8% 1% Other catheter related events 5% 1% Sepsis 15% 4% Decreased appetite 14% 15% Vomiting 13% 13% Infection 13% 9% Hyperhidrosis 12% 11% Chills 10% 7% Neuropathy peripheral 9% 8% Thrombocytopenia 6% 6% Pruritus 5% 6% Retinal detachment has been observed in subjects with CMV retinitis both before and after initiation of therapy with ganciclovir.
Its relationship to therapy with ganciclovir is unknown.
Retinal detachment occurred in 11% of patients treated with Ganciclovir Injection Retinal Detachment: Retinal detachment has been observed in subjects with CMV retinitis both before and after initiation of therapy with ganciclovir.
Its relationship to therapy with ganciclovir is unknown.
Retinal detachment occurred in 11% of patients treated with Ganciclovir Injection and in 8% of patients treated with ganciclovir capsules.
Table 3.
Selected Laboratory Abnormalities in Trials for Treatment of CMV Retinitis CMV Retinitis Treatment Pooled data from Treatment Studies: ICM 1653, ICM 1774 and AVI 034 Laboratory Abnormalities Ganciclovir Injection Mean time on therapy = 103 days, including allowed re-induction treatment periods 5 mg/kg/day (N=175) % Ganciclovir Capsules Mean time on therapy = 91 days, including allowed re-induction treatment periods 3000 mg/day (N=320) % Neutropenia with Absolute Neutrophil Count (ANC) per mcL: < 500 25% 18% 500 < 749 14% 17% 750 < 1000 26% 19% Anemia with Hemoglobin (g/dL): < 6.5 g/dL 5% 2% 6.5 < 8.0 16% 10% 8.0 < 9.5 26% 25% Serum Creatinine (mg/dL): ≥ 2.5 2% 1% ≥ 1.5 – < 2.5 14% 12% There have been three controlled clinical trials of Ganciclovir Injection for the prevention of CMV disease in transplant recipients.
Selected laboratory abnormalities are summarized in Table 4 and Table 5 below.
Adverse Reactions in Transplant Recipients: There have been three controlled clinical trials of Ganciclovir Injection for the prevention of CMV disease in transplant recipients.
Selected laboratory abnormalities are summarized in Table 4 and Table 5 below.
Table 4 shows the frequency of neutropenia and thrombocytopenia and Table 5 shows the frequency of elevated serum creatinine values observed in these trials Table 4 shows the frequency of neutropenia and thrombocytopenia and Table 5 shows the frequency of elevated serum creatinine values observed in these trials [see Clinical Studies (14.2) ] .
Table 4.
Laboratory Abnormalities in Controlled Trials Transplant Recipients who Received Ganciclovir Injection, Placebo or Control Ganciclovir Injection Heart Allograft Study ICM 1496.
Mean duration of treatment = 28 days Bone Marrow Allograft Study ICM 1570 and ICM 1689.
Mean duration of treatment = 45 days Ganciclovir Injection (n=76) Placebo (n=73) Ganciclovir Injection (n=57) Control (n=55) Neutropenia Absolute Neutrophil Count (ANC) per mcL < 500 4% 3% 12% 6% 500-1000 3% 8% 29% 17% Total ANC ≤ 1000/mcL 7% 11% 41% 23% Thrombocytopenia Platelet count per mcL < 25,000 3% 1% 32% 28% 25,000-50,000 5% 3% 25% 37% Total Platelet Count ≤ 50,000/mcL 8% 4% 57% 65% Table 5.
Serum Creatinine Levels in Controlled Trials - Transplant Recipients who Received Ganciclovir Injection or Placebo Serum Creatinine Levels (mg/dL) Heart Allograft ICM 1496 Bone Marrow Allograft ICM 1570 Bone Marrow Allograft ICM 1689 Ganciclovir Injection (n=76) Placebo Ganciclovir Injection Control Ganciclovir Injection Placebo (n=73) (n=20) (n=20) (n=37) (n=35) ≥ 2.5 mg/dL 18% 4% 20% 0% 0% 0% ≥ 1.5 - < 2.5 58% 69% 50% 35% 43% 44% Other Adverse Reactions in Clinical Trials in Patients with CMV Retinitis and in Transplant Recipients Adverse drug reactions with Ganciclovir Injection or ganciclovir capsules in controlled clinical studies in either subjects with AIDS or transplant recipients are listed below Adverse drug reactions with Ganciclovir Injection or ganciclovir capsules in controlled clinical studies in either subjects with AIDS or transplant recipients are listed below [see Clinical Studies (14) ].
All these events occurred in at least 3 subjects.
pancytopenia, bone marrow failure Blood and lymphatic disorders: pancytopenia, bone marrow failure arrhythmia Cardiac disorders: arrhythmia : tinnitus, ear pain, deafness Ear and labyrinth disorders : tinnitus, ear pain, deafness : visual impairment, vitreous disorders, eye pain, conjunctivitis, macular edema Eye disorders : visual impairment, vitreous disorders, eye pain, conjunctivitis, macular edema : nausea, abdominal pain, dyspepsia, flatulence, constipation, mouth ulceration, dysphagia, abdominal distention, pancreatitis, gastrointestinal perforation, eructation, dry mouth Gastrointestinal disorders : nausea, abdominal pain, dyspepsia, flatulence, constipation, mouth ulceration, dysphagia, abdominal distention, pancreatitis, gastrointestinal perforation, eructation, dry mouth : fatigue, injection site inflammation, edema, pain, malaise, asthenia, chest pain, multiple organ failure General disorders and administration site conditions : fatigue, injection site inflammation, edema, pain, malaise, asthenia, chest pain, multiple organ failure : hypersensitivity Immune system disorders : hypersensitivity candida infections including oral candidiasis, upper respiratory infection, influenza, urinary tract infection, cellulitis Infections and infestations: candida infections including oral candidiasis, upper respiratory infection, influenza, urinary tract infection, cellulitis : blood alkaline phosphatase increased, hepatic function abnormal, aspartate aminotransferase increased, alanine aminotransferase increased, creatinine clearance decreased Investigations : blood alkaline phosphatase increased, hepatic function abnormal, aspartate aminotransferase increased, alanine aminotransferase increased, creatinine clearance decreased weight decreased Metabolism and nutrition disorders: weight decreased back pain, myalgia, arthralgia, muscle spasms, leg cramps, myasthenia Musculoskeletal and connective tissue disorders: back pain, myalgia, arthralgia, muscle spasms, leg cramps, myasthenia headache, insomnia, dizziness, paresthesia, hypoesthesia, seizure, somnolence, dysgeusia (taste disturbance), tremor Nervous system disorders: headache, insomnia, dizziness, paresthesia, hypoesthesia, seizure, somnolence, dysgeusia (taste disturbance), tremor depression, confusional state, anxiety, agitation, psychotic disorder, thinking abnormal, abnormal dreams Psychiatric disorders: depression, confusional state, anxiety, agitation, psychotic disorder, thinking abnormal, abnormal dreams kidney failure, renal function abnormal, urinary frequency, hematuria Renal and urinary disorders: kidney failure, renal function abnormal, urinary frequency, hematuria cough, dyspnea Respiratory, thoracic and mediastinal disorders: cough, dyspnea dermatitis, alopecia, dry skin, urticaria, rash Skin and subcutaneous tissues disorders: dermatitis, alopecia, dry skin, urticaria, rash : hypotension, hypertension, phlebitis, vasodilation Vascular disorders : hypotension, hypertension, phlebitis, vasodilation 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of Ganciclovir Injection The following adverse reactions have been identified during post-approval use of Ganciclovir Injection or ganciclovir capsules.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
: hemolytic anemia, agranulocytosis, granulocytopenia Blood and lymphatic disorders : hemolytic anemia, agranulocytosis, granulocytopenia cardiac arrest, conduction disorder, torsade de pointes, ventricular tachycardia Cardiac disorders: cardiac arrest, conduction disorder, torsade de pointes, ventricular tachycardia congenital anomaly Congenital, familial and genetic disorders: congenital anomaly inappropriate antidiuretic hormone secretion Endocrine disorders: inappropriate antidiuretic hormone secretion cataracts, dry eyes Eye disorders: cataracts, dry eyes intestinal ulcer Gastrointestinal disorders: intestinal ulcer cholelithiasis, cholestasis, hepatic failure, hepatitis Hepatobiliary disorders: cholelithiasis, cholestasis, hepatic failure, hepatitis anaphylactic reaction, allergic reaction, vasculitis Immune system disorders: anaphylactic reaction, allergic reaction, vasculitis blood triglycerides increased Investigations: blood triglycerides increased acidosis, hypercalcemia, hyponatremia Metabolism and nutrition disorders: acidosis, hypercalcemia, hyponatremia arthritis, rhabdomyolysis Musculoskeletal and connective tissue disorders: arthritis, rhabdomyolysis dysesthesia, dysphasia, extrapyramidal disorder, facial paralysis, amnesia, anosmia, myelopathy, cerebrovascular accident, third cranial nerve paralysis, aphasia, encephalopathy, intracranial hypertension Nervous system disorders: dysesthesia, dysphasia, extrapyramidal disorder, facial paralysis, amnesia, anosmia, myelopathy, cerebrovascular accident, third cranial nerve paralysis, aphasia, encephalopathy, intracranial hypertension irritability, hallucinations Psychiatric disorders: irritability, hallucinations renal tubular disorder, hemolytic uremic syndrome Renal and urinary disorders: renal tubular disorder, hemolytic uremic syndrome infertility, testicular hypotrophy Reproductive system and breast disorders: infertility, testicular hypotrophy bronchospasm, pulmonary fibrosis Respiratory, thoracic and mediastinal disorders: bronchospasm, pulmonary fibrosis : exfoliative dermatitis, Stevens-Johnson syndrome Skin and subcutaneous tissues disorders : exfoliative dermatitis, Stevens-Johnson syndrome peripheral ischemia Vascular disorders: peripheral ischemia